This is a research study for individuals who have cancer associated with human papillomavirus (HPV) and are being treated with radiation as part of standard care for their cancer. Doctors leading this study will use blood tests to find out if they can detect the HPV virus in the blood of study participants before, during, and after radiation treatment. They will also collect blood and archival tumor tissue (from a previous biopsy) to perform other tests in the future that could provide more information about HPV-associated cancers and how they respond to treatment. Participation in this study will last approximately 2 years.
Stage I-III anal cancer or stage I-IVA cervical cancer that is p16+ based on immunohistochemistry.
Age ≥ 18 years
Planned to undergo radiation therapy as definitive treatment, with or without concurrent systemic therapy
Anal carcinoma not associated with HPV-16, 18, 31, 33, or 35 will be removed from the
Planned to undergo radiation therapy as an adjuvant or post-operative therapy
University of Chicago
Lead sponsor